Science

Mohamed Gouda: Selinexor in Combination with Immune Checkpoint Inhibition in Uveal Melanoma

Mohamed Alaa Gouda/researchgate.net

Jan 25, 2025, 04:09

Mohamed Gouda: Selinexor in Combination with Immune Checkpoint Inhibition in Uveal Melanoma

Mohamed Gouda, Clinical Fellow at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by him and colleagues published in Journal of Immunotherapy and Precision Oncology:

“Now published in JIPO: Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma.

And interview with Dr. Sapna Patel about the study’s highlights.”

“Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial “

Authors: Mohamed Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna Patel.

Mohamed Gouda: Selinexor in Combination with Immune Checkpoint Inhibition in Uveal Melanoma

More posts featuring Mohamed Gouda.

Abdulrazzak Zarifa Ashabari Sprenger Bettzy Stephen cancer Funda Meric-Bernstam Isabella Glitza Oliva Mohamed Derbala Mohamed Gouda OncoDaily Oncology Sapna Patel selinexor Serdar Gurses Uveal melanoma Yali Yang Yanyan Tian

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC